Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump's new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

US President Donald Trump has signed an executive order aimed at reducing drug costs for Americans, by up to 80% immediately.

The move immediately hit Australia's pharmaceutical industry as 3 ASX pharmaceutical stocks crashed up to 10% shortly after the announcement.

Telix Pharmaceuticals Ltd (ASX: TLX) shares dropped 8.7% on Monday, to $24.47. The stock price has since recovered some losses, increasing 3.6% to $25.36 and has continued an upward trajectory today. It still has some way to go before it reaches the $29-mark seen earlier this month.

Similarly, Neuren Pharmaceuticals Ltd (ASX: NEU) shares dropped 9.56% at the close on Monday, to $12.02. The company share price has recovered some losses over the past 24 hours, rising 2.6% at the close yesterday. There are indications of another small increase today.

Clarity Pharmaceuticals Ltd (ASX: CU6) also followed the same trend. Its shares dropped 8.64% on Monday to $2.22 before rising 15.3% yesterday. The pharmaceuticals stock has experienced a steady decline since October last year before bottoming out in April.

What is Trump's executive order, and why is it affecting ASX pharmaceutical stocks?

As news.com reported:

What that means, in essence, is the US government will buy drugs at the lowest price they're being purchased for in other countries…Mr Trump is of the opinion that this will lead to lower prices in the United States, and that pharmaceutical companies will compensate by charging the rest of the world more.

The order, which has been described as a "game changer", casued an immediate drop of share prices for 3 ASX pharmaceutical stocks following fears that they will be forced to lower their drug prices. 

"Starting today, the United States will no longer subsidise the health care of foreign countries, which is what we were doing, we're subsidising others' health care, in countries where they pay a small fraction of what, for the same drug, that what we pay," US President Trump told reporters Monday at the White House. 

He said that big pharmaceutical companies will either have to abide by his new principle voluntarily. If not, he'll use the power of the federal government to ensure "we are paying the same price of other countries". 

The President tried to implement something similar during his first term in office, but was prevented by the courts. He slammed the idea as ineffective when Kamala Harris suggested it during last year's election campaign. Now he appears to have recommitted to the policy.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up more than 800% in a year. Why this ASX medical tech stock just hit an all-time high

4DMedical shares have surged over 800% as US hospital adoption and FDA clearance drive momentum.

Read more »

A retiree relaxing in the pool and giving a thumbs up.
Healthcare Shares

1 ASX dividend stock down 36% I'd buy right now

This business looks like it’s priced too cheaply.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »